Content Hub

Lorem ipsum dolor sit amet consectetur adipiscing elit. Dolor sit amet consectetur adipiscing elit quisque faucibus.

mountain climb steep cliff climber struggle
Content Channel

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
Large layoffs of employees Wooden figures of people going to the exit

J&J dismisses 56 from HQ as part of orthopedics separation

acquisition merger MA chess game

CordenPharma to snap up peptide API maker with US, China sites